Last reviewed · How we verify
NCT06632054
Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs
NA trial testing Text Message Reminders in Colon Cancer in 1,283 participants. Completed in 15 July 2025.
24 June 2025
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 1,283 |
| Start date | 7 April 2025 |
| Primary completion | 24 June 2025 |
| Estimated completion | 15 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Text Message Reminders
Conditions studied
- Colon Cancer — all drugs for Colon Cancer →
Sponsor
NYU Langone Health — full company profile →
Who can join
18 and older, any sex, with Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The research team will compare the efficacy of targeted text message reminders against currently used phone call reminders at increasing patient completion of fecal immunochemical test (FIT) for colon cancer screening.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Behaviorally Informed Text Messaging to Promote Colon Cancer Screening: A Quality Improvement Randomized Clinical Trial.
Korostoff-Larsson O, King WC, Pelegri E, Colella D, et al · · 2026 · PMID 42024386 · DOI 10.1001/jamanetworkopen.2026.7122
Verify or expand the search:
- PubMed search for NCT06632054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Text Message Reminders
Trials testing the same drug.
- NCT03103854 — Novel Strategies to Improve Cardiometabolic Status and Adherence to Exercise Regimens in Patients at High Risk for Cardi · NA · unknown
Other recruiting trials for Colon Cancer
Currently open trials in the same condition.
- NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
- NCT07279077 — Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advance · Phase 2 · recruiting
- NCT07205965 — The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors · NA · active not recruiting
- NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
- NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06632054 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 19 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06632054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing